Safety and efficacy of panitumumab following cetuximab: Retrospective review of the Memorial Sloan-Kettering experience

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 353-360

  Power, Derek G ^a   Shah, Manish A ^a   Asmis, Timothy R ^a   Garcia, Joaquin J ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cetuximab; Hypersensitivity reactions; Metastatic colorectal cancer; Panitumumab

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ACNE; ANAPHYLAXIS; CANCER COMBINATION CHEMOTHERAPY; CHILL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE DISORDER; FLUSHING; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; LIP DISEASE; LOADING DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; NAIL; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SKIN TOXICITY; SWELLING; URTICARIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 77952239903     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9268-y     Document Type: Review

References (46)

1. C Bokemeyer I Bondarenko A Makhson, et al. 2008 Fluorouracil, Leucovorin, and Oxaliplatin with and without Cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 29 29
2. Rougier P, Stroiakovski D, Köhne C et al (2009) Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): Updated survival data and influence of KRAS status on outcome in the CRYSTAL study. American Society of Clinical Oncology-Gastrointestinal Cancer Symposium, Abstract # 443
3. DJ Jonker CJ O'Callaghan CS Karapetis, et al. 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040 2048 10.1056/NEJMoa071834 10.1056/NEJMoa071834 1:CAS:528:DC%2BD2sXhtlWis7rI 18003960 (Pubitemid 350106711)
4. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 10.1056/NEJMoa033025 10.1056/NEJMoa033025 1:CAS:528:DC%2BD2cXlvFGitbk%3D 15269313 (Pubitemid 38944402)
5. G Folprecht MP Lutz P Schoffski, et al. 2006 Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann Oncol 17 450 456 10.1093/annonc/mdj084 10.1093/annonc/mdj084 1:STN:280:DC%2BD287ht1Olug%3D%3D 16303861 (Pubitemid 43329582)
6. LB Saltz NJ Meropol PJ Loehrer Sr, et al. 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 10.1200/JCO.2004.10. 182 10.1200/JCO.2004.10.182 1:CAS:528:DC%2BD2cXpsVGktLw%3D 14993230 (Pubitemid 41079832)
7. J Tabernero E Van Cutsem E Diaz-Rubio, et al. 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232 10.1200/JCO.2007.13.2183 10.1200/JCO.2007.13.2183 1:CAS:528:DC%2BD2sXhsVKnsbzI 18024868 (Pubitemid 350232254)
8. A Cervantes E Casado E Van Cutsem 2005 Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study Eur J Cancer Suppl 3 181 182
9. H Wilke R Glynne-Jones J Thaler, et al. 2008 Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study J Clin Oncol 26 5335 5343 10.1200/JCO.2008.16.3758 10.1200/JCO.2008.16.3758 1:CAS:528:DC%2BD1MXhslCmtA%3D%3D 18854570
10. AF Sobrero J Maurel L Fehrenbacher, et al. 2008 EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2311 2319 10.1200/JCO.2007.13.1193 10.1200/JCO.2007.13.1193 1:CAS:528:DC%2BD1cXntVOltrk%3D 18390971
11. E Van Cutsem M Peeters S Siena, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 1658 1664 10.1200/JCO.2006.08.1620 10.1200/JCO.2006.08.1620 17470858 (Pubitemid 46797944)
12. J Berlin J Posey S Tchekmedyian, et al. 2007 Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer Clin Colorectal Cancer 6 427 432 10.3816/CCC.2007.n.011 10.3816/CCC.2007.n.011 1:CAS:528:DC%2BD2sXlsFGnurc%3D 17531105 (Pubitemid 46658516)
13. M Mano Y Humblet 2008 Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer Nat Clin Pract Oncol 5 415 425 10.1038/ncponc1136 10.1038/ncponc1136 1:CAS:528:DC%2BD1cXnslyktL0%3D 18506165 (Pubitemid 351958966)
14. KY Chung J Shia NE Kemeny, et al. 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810 10.1200/JCO.2005.08.037 10.1200/JCO.2005.08.037 1:CAS:528:DC%2BD2MXjt1Ckuro%3D 15677699 (Pubitemid 46211358)
15. G Milano MC Etienne-Grimaldi L Dahan, et al. 2008 Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer Ann Oncol 19 2033 2038 10.1093/annonc/mdn416 10.1093/annonc/mdn416 1:STN:280: DC%2BD1cjlsFeisA%3D%3D 18632722
16. C Bokemeyer I Bondarenko JT Hartmann, et al. 2008 KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience J Clin Oncol 26 4000 10.1200/JCO.2007.15.2991
17. CS Karapetis S Khambata-Ford DJ Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 10.1056/NEJMoa0804385 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J 18946061
18. A Lievre JB Bachet V Boige, et al. 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 10.1200/JCO.2007.12.5906 10.1200/JCO.2007.12. 5906 1:CAS:528:DC%2BD1cXitVGntLc%3D 18202412 (Pubitemid 351171687)
19. A Lievre JB Bachet D Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 10.1158/0008-5472.CAN-06-0191 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D 16618717
20. E Van Cutsem I Lang G D'haens, et al. 2008 KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience J Clin Oncol 26 2 10.1200/JCO.2007.14.5144
21. RG Amado M Wolf M Peeters, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 10.1200/JCO.2007.14.7116 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D 18316791
22. W De Roock H Piessevaux J De Schutter, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 515 10.1093/annonc/mdm496 10.1093/annonc/mdm496 17998284 (Pubitemid 351325672)
23. S Khambata-Ford CR Garrett NJ Meropol, et al. 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 10.1200/JCO.2006.10.5437 10.1200/JCO.2006.10.5437 1:CAS:528: DC%2BD2sXhtVWqs7rF 17664471 (Pubitemid 47325606)
24. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 10 10
25. D Helbling M Borner 2007 Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab Ann Oncol 18 963 964 10.1093/annonc/mdm130 10.1093/annonc/mdm130 1:STN:280:DC%2BD2s3nvVOktg%3D%3D 17488734 (Pubitemid 47054100)
26. A Langerak G River E Mitchell, et al. 2009 Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports Clin Colorectal Cancer 8 49 54 10.3816/CCC.2009.n. 008 10.3816/CCC.2009.n.008 1:CAS:528:DC%2BD1MXjtVylsrk%3D 19203897
27. MW Saif J Peccerillo V Potter 2008 Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature Cancer Chemother Pharmacol 10 10
28. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214 10.1002/1097-0142(19810101) 47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1002/1097-0142(19810101)47: 1<207::AID-CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D 7459811
29. JR Hecht E Mitchell T Chidiac, et al. 2008 A randomized phase IIIB Trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 29 29
30. J Tol M Koopman A Cats, et al. 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 563 572 10.1056/NEJMoa0808268 10.1056/NEJMoa0808268 1:CAS:528:DC%2BD1MXhsFyitrw%3D 19196673
31. P Pfeiffer D Nielsen M Yilmaz, et al. 2007 Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil Acta Oncol 46 697 701 10.1080/02841860601009455 10.1080/02841860601009455 1:CAS:528: DC%2BD2sXmtlWms7g%3D 17562448 (Pubitemid 46911904)
32. E Van Cutsem CH Kohne E Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 10.1056/NEJMoa0805019 10.1056/NEJMoa0805019 19339720
33. M Peeters G Wilson M Ducreux, et al. 2008 Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results J Clin Oncol 26 4064
34. Douillard J, Siena S, Cassidy J et al (2008) Phase III study (PRIME/20050203) of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety data. American Society of Clinical Oncology-Gastrointestinal Cancer Symposium, Abstract # 443
35. D Freeman J Sun R Bass, et al. 2008 Panitumumab and cetuximab epitope mapping and in vitro activity J Clin Oncol 26 14536
36. Erbitux®, (cetuximab) 2007 Prescribing information Imclone Systems, Inc Branchburg, NJ Erbitux®, (cetuximab) (2007) Prescribing information. Imclone Systems, Inc, Branchburg, NJ. www.erbitux.com
37. Vectibix®, (panitumumab) 2008 Prescribing information Amgen, Inc Thousand Oaks, CA Vectibix®, (panitumumab) (2008) Prescribing information. Amgen, Inc, Thousand Oaks, CA. www.vectibix.com
38. P Pfeiffer D Nielsen J Bjerregaard, et al. 2008 Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil Ann Oncol 19 1141 1145 10.1093/annonc/mdn020 10.1093/annonc/mdn020 1:STN:280: DC%2BD1czktlShuw%3D%3D 18281264 (Pubitemid 351796340)
39. J Tabernero P Pfeiffer A Cervantes 2008 Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13 113 119 10.1634/theoncologist.2007-0201 10.1634/theoncologist.2007-0201 1:CAS:528:DC%2BD1cXktVSgsrY%3D 18305055 (Pubitemid 351342574)
40. M Peeters E Van Cutsem J Berlin, et al. 2007 Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials J Clin Oncol 25 4138
41. BH O'Neil R Allen DR Spigel, et al. 2007 High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history J Clin Oncol 25 3644 3648 10.1200/JCO.2007.11. 7812 10.1200/JCO.2007.11.7812 17704414 (Pubitemid 47372602)
42. J Cerman B Melichar M Cermanova D Solichova 2008 Management of severe infusion reactions after cetuximab Acta Oncol 47 1609 1611 10.1080/ 02841860802123204 10.1080/02841860802123204 18607870
43. MW Saif J Peccerillo V Potter 2009 Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature Cancer Chemother Pharmacol 63 1017 1022 10.1007/s00280-008-0831-6 10.1007/s00280-008-0831-6 18781300
44. DL Nielsen P Pfeiffer BV Jensen 2009 Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab Ann Oncol 20 798 10.1093/annonc/mdp040 10.1093/annonc/mdp040 1:STN:280: DC%2BD1M3jt1yrsg%3D%3D 19254943
45. NCT00418938 (2009) SPIRITT-Q2W FOLFIRI Regimen Plus Panitumumab or a Q2W FOLFIRI Regimen Plus Bevacizumab for 2nd-Line mCRC. www.clinicaltrials.com - last updated 05/07/2009
46. S Benvenuti A Sartore-Bianchi F Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643 2648 10.1158/0008-5472.CAN-06-4158 10.1158/0008-5472.CAN-06- 4158 1:CAS:528:DC%2BD2sXivV2ns7w%3D 17363584 (Pubitemid 46548951)